Comparison
Omega-3 (DHA/EPA) vs Metformin
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
Metformin
Anti-diabetic medication studied for longevity. AMPK activator. Glucose normalization.
| Field | Omega-3 (DHA/EPA) | Metformin |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–3000mg | 500–2000mg |
| Half-life | 24h | — |
| Onset | — | — |
| Evidence | EVIDENCEA | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 5200 | 23000 |
The comparison in plain English
Auto-generated from dataOmega-3 (DHA/EPA) and Metformin are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. Metformin Anti-diabetic medication studied for longevity.
Bottom line
Omega-3 (DHA/EPA) (evidence A, safety 5/5) matches the evidence base of Metformin (evidence A, safety 4/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.
Choose Metformin if
Metformin is the better fit when your goal aligns with its mechanism (Activates AMP-activated protein kinase (AMPK), the cellular energy sensor that mimics caloric restriction signalling) and the dose range (500–2000mg) suits your protocol. Half-life is —h.